CD34 and acute myeloid leukemia: For example, ARV-825, a BET/BRD4 inhibitor targeting c-Myc, can downregulate Wnt–β-catenin signaling, thereby decreasing the CD34+CD38−CD90−CD45RA+ leukemic stem cell population in AML [155].